| Systematic (IUPAC) name | |
|---|---|
| 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| Pregnancy cat. | Risk neonatal thrombocytopenia in 3rd trimester[1] |
| Legal status | POM (UK) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | 96% |
| Metabolism | extensive |
| Half-life | 3-4 hours[2] |
| Identifiers | |
| CAS number | 73-48-3 |
| ATC code | C03AA01 |
| PubChem | CID 2315 |
| DrugBank | APRD00666 |
| ChemSpider | 2225 |
| UNII | 5Q52X6ICJI |
| KEGG | D00650 |
| ChEBI | CHEBI:3013 |
| ChEMBL | CHEMBL1684 |
| Chemical data | |
| Formula | C15H14F3N3O4S2 |
| Mol. mass | 421.415 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Bendroflumethiazide (INN), formerly bendrofluazide (BAN), is a thiazide diuretic used to treat hypertension.
It is also a fairly cheap drug, made cheap through mass production. Normal pharmaceutical trade prices vary from £0.10 - £0.20 for a 28 calendar pack of Bendroflumethiazide 2.5 tablets. Bendroflumethiazide (bendrofluazide) is a thiazide diuretic which works by inhibiting sodium absorption at the beginning of the distal convoluted tubule (DCT). Potassium is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).
Common adverse effects
Rare adverse effects
|
||||||||
|
||||||||||||||||||||||||||||||||||||||||||